RBS-2418 is under clinical development by Riboscience and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RBS-2418’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RBS-2418 is under development for treatment of solid tumor, advanced unresectable, recurrent or refractory metastatic adrenal cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma. The therapeutic candidate is a selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). It is administered by oral route.
For a complete picture of RBS-2418’s drug-specific PTSR and LoA scores, buy the report here.